 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
INHL:NASDAQ Inhale Therapeutics (Palto Alto, CA) is a cutting-edge biotech which is developing pulmonary (that is inhaled) delivery systems for biopharmaceuticals. They have multiple partnerships with other biotech and pharmaceutical firms. They are on the verge of changing the entire paradigm for the biotech industry. If you had a choice, would you rather have an injection or breathe in a puff of powder? Pulmonary delivery provides a large surface area for drug delivery, extensive vasculature, a relatively thin, permeable memrbane, and low extracellualr enzymatic activity, which all favor a rapid and significant absorption compared to other non-injectable routes. In addition, having a powder aerosol formulation allows for greater drug stability, better patient compliance, and more flexibility. Most importantly, they are an partneship with Pfizer (Groton, CT) on a Phase II trial of an inhaled formualtion of insulin. So far, the data show that the insulin can be absorbed and successfully lower blood glucose levels. Consider that insulin is about an $870 market and is growing at 11% annually. This could be a potential home run and could change the way the biotech industry thinks about formulating and delivering drugs. Rick Costantino | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |